Zejula 100 mg hard capsules
Sponsors
Arcagy Gineco, Tesaro Inc., Glaxosmithkline Research & Development Limited, Unicancer, Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
Conditions
Advanced Biliary Cancer (ABC)Advanced ovarianAdvanced solid tumorCancerFIGO stage III/IV (except FIGO IIIA2 without nodal involvement)Multiple myelomaNon-Hodgkin lymphomaOvarian Neoplasms
Phase 2
An Open-Label, Multicenter, Long-term Treatment Extension Study in Subjects Who Have Completed a Prior GlaxoSmithKline/TESARO-Sponsored Niraparib Study and are Judged by the Investigator to Benefit from Continued Treatment with Niraparib
RecruitingCTIS2023-506618-29-00
Start: 2021-09-22Target: 8Updated: 2025-10-22
OPAL Master Protocol: A Phase 1B/2 Multicohort Umbrella Study to Evaluate the Safety and Efficacy of Novel Treatments and/or Combinations of Treatments in Participants with Ovarian Cancer (OPAL) (PR-3000-02-005/213357)
Cohort C: Open-label Phase 2, Randomized, Controlled Multicenter Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants with Homologous Recombination- Deficient Stage III/IV Ovarian Cancer
CompletedCTIS2023-505097-16-00
Start: 2022-04-04End: 2025-03-31Target: 15Updated: 2025-01-14
A Dutch National Study on behalf of the Center for Personalized Cancer Treatment (CPCT) to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to determine the Potential Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile: The Drug Rediscovery Protocol (DRUP trial)
RecruitingCTIS2023-509152-33-00
Start: 2016-07-25Target: 3000Updated: 2025-12-19
ProTarget - A Danish Nationwide Clinical Trial on Targeted Anti‐Cancer Treatment based on Genomic Profiling
RecruitingCTIS2023-510527-29-00
Start: 2020-09-01Target: 600Updated: 2025-04-25
A Randomized Study of Paclitaxel – Carboplatin followed by maintenance Niraparib compared to Paclitaxel – Carboplatin – Bevacizumab followed by maintenance Niraparib + Bevacizumab in Patients With Advanced Ovarian Cancer Following a Front-Line Complete Cytoreductive Surgery (NIRVANA-1 study)
RecruitingCTIS2023-504166-37-00
Start: 2022-02-01Target: 336Updated: 2025-11-07
An international multicentric randomized phase II evaluating dostarlimab in combination with niraparib versus niraparib alone compared to chemotherapy in the treatment of metastatic or recurrent endometrial or ovarian carcinosarcoma after at least one line of chemotherapy : ROCSAN study
Not yet recruitingCTIS2024-516782-36-00
Target: 135Updated: 2025-12-10
A Phase II, Randomized, Trial of Niraparib Versus Best Supportive Careas Maintenance Treatment In Patients With Locally Advanced Or Metastatic Urothelial Cancer Whose Disease Did Not Progress After Completion Of First-line Platinum-containing Chemotherapy (MEET URO 12)
Not yet recruitingCTIS2024-519519-32-00
Target: 77Updated: 2025-02-17
Phase 3
SAFIR ABC10 : Molecular targeted maintenance therapy versus standard of care in advanced biliary cancer: an international, randomised, controlled, open-label, platform phase 3 trial
RecruitingCTIS2023-508100-38-00
Start: 2024-06-24Target: 450Updated: 2025-05-14
Niraparib vs Niraparib in combination with Bevacizumab in patients with carboplatinum-taxane based chemotherapy in advanced ovarian cancer (A multicentre randomised phase III trial)
RecruitingCTIS2024-516066-11-00
Start: 2022-08-31Target: 970Updated: 2025-11-21